RT Journal Article
T1 Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer.
A1 Conde-Muíño, Raquel
A1 Cuadros, Marta
A1 Zambudio, Natalia
A1 Segura-Jiménez, Inmaculada
A1 Cano, Carlos
A1 Palma, Pablo
K1 Adenocarcinoma
K1 Marcadores biológicos
K1 Quimiorradioterapia
K1 Humanos
K1 Terapia neoadyuvante
K1 Neoplasias del recto
K1 Pronóstico
AB There has been a high local recurrence rate in rectal cancer. Besides improvements in surgical techniques, both neoadjuvant short-course radiotherapy and long-course chemoradiation improve oncological results. Approximately 40-60% of rectal cancer patients treated with neoadjuvant chemoradiation achieve some degree of pathologic response. However, there is no effective method of predicting which patients will respond to neoadjuvant treatment. Recent studies have evaluated the potential of genetic biomarkers to predict outcome in locally advanced rectal adenocarcinoma treated with neoadjuvant chemoradiation. The articles produced by the PubMed search were reviewed for those specifically addressing a genetic profile's ability to predict response to neoadjuvant treatment in rectal cancer. Although tissue gene microarray profiling has led to promising data in cancer, to date, none of the identified signatures or molecular markers in locally advanced rectal cancer has been successfully validated as a diagnostic or prognostic tool applicable to routine clinical practice.
PB Hindawi Publishing Corporation
YR 2015
FD 2015
LK http://hdl.handle.net/10668/2182
UL http://hdl.handle.net/10668/2182
LA en
NO Conde-Muíño R, Cuadros M, Zambudio N, Segura-Jiménez I, Cano C, Palma P. Predictive Biomarkers to Chemoradiation in Locally Advanced Rectal Cancer. Biomed Res Int. 2015; 921435
NO Journal Article; Review;
DS RISalud
RD Apr 11, 2025